Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05514899 · ClinicalTrials.gov registry record · Phase 2
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
A Phase 2 study of HIV and Cannabis, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT05514899: Recruiting Phase 2 study of HIV and Cannabis, sponsored by University of California, San Diego.
NCT05514899 is a Phase 2 study of HIV and Cannabis that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 90 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05514899, a Phase 2 study of HIV and Cannabis, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This study has the potential to contribute to a more complete understanding of the independent and combined effects of cannabis use and HIV on the brain and on inflammation. Such knowledge may inform future strategies for treating brain disease and inflammation. Participants will be randomly assigned to one of two groups, both of which will receive the same treatment in a different order over a period of about 6 weeks. The visits include physical examinations, blood tests, and other procedures designed to monitor subject safety and measure the effects of the study drug.
Primary Outcome
A composite marker of inflammation, comprising the first component (PC1, a unitless measure) of the principal component analysis (PCA) of 7 soluble biomarkers in blood (soluble CD163 \[sCD163\], interferon gamma \[IFN-gamma\], interleukin 6 \[IL-6\], C-reactive protein \[CRP\], CC motif chemokine ligand 2 \[CCL2\], neopterin and soluble tumor necrosis factor - type II \[sTNFRII\]), all measured in picograms/milliliter
Conditions Studied
Interventions
- DRUG THC
- DRUG CBD
Study Locations (1)
California
- HIV Neurobehavioral Research Program (HNRP) - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 2 |
What NCT05514899 shows while recruiting
NCT05514899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (80% lower).
The record links to 6 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which THC is the first listed.
NCT05514899 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05514899 about?
NCT05514899 is a clinical study titled "Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV". This study has the potential to contribute to a more complete understanding of the independent and combined effects of cannabis use and HIV on the brain and on inflammation. Such knowledge may inform future strategies for treating brain disease and inflammation. Participants will be randomly assigne...
What is the current status of trial NCT05514899?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2023-09-01. Estimated completion is 2027-10-31.
What conditions does trial NCT05514899 study?
This clinical trial studies the following conditions: HIV, Cannabis, Microbiome, THC, Neuroinflammatory Disease.
What interventions are being tested in trial NCT05514899?
The interventions under investigation include: THC (DRUG), CBD (DRUG).
Who is sponsoring clinical trial NCT05514899?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05514899 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05514899's enrollment target sits among peer trials
90 165th of 303 higher than 136 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Improving Physical Ability and Cellular Senescence Elimination in HIV
RECRUITING · Phase 2
-
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
RECRUITING · Phase 2
-
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
RECRUITING · Phase 2
-
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI